Transcriptional Correlates of Disease Outcome in Anticoagulant-Treated Non-Human Primates Infected with Ebolavirus

PLoS Neglected Tropical Diseases

Volumn 8, Issue 7, 2014, Pages

  Garamszegi, Sara ^a   Yen, Judy Y ^a,b   Honko, Anna N ^c   Geisbert, Joan B ^d   Rubins, Kathleen H ^e   Geisbert, Thomas W ^d   Xia, Yu ^a,f   Hensley, Lisa E ^g   Connor, John H ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e NASA HEADQUARTERS   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; MYOCARDIN; PROTEIN P53;

ARTICLE; EBOLA VIRUS; GENE EXPRESSION; MICROARRAY ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIMATE DISEASE; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTOMICS; VALIDATION PROCESS; VIRUS REPLICATION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE EXPRESSION PROFILING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MONONUCLEAR CELL; PATHOGENICITY; PATHOLOGY; RHESUS MONKEY; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GENE EXPRESSION PROFILING; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MICROARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84905460388     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003061     Document Type: Article

References (83)

1. (2011) Virus taxonomy: classification and nomenclature of viruses: Ninth Report of the International Committee on Taxonomy of Viruses; King AMQ, Adams, M.J., Carstens, E.B., and Lefkowitz, E.J., editor. San Diego: Elsevier Academic Press.
2. Feldmann H, Geisbert TW, (2011) Ebola haemorrhagic fever. Lancet 377: 849-862.
3. Feldmann H, Jones S, Klenk HD, Schnittler HJ, (2003) Ebola virus: from discovery to vaccine. Nat Rev Immunol 3: 677-685.
4. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3: e2.
5. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26: 6894-6900.
6. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83: 7296-7304.
7. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362: 1953-1958.
8. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375: 1896-1905.
9. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, et al. (2007) Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 196 Suppl 2: S390-399.
10. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
11. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, et al. (2009) Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 4: e5308.
12. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ, (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
13. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163: 2347-2370.
14. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163: 2371-2382.
15. Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW, (2005) Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med 5: 761-772.
16. Flint SJ, Enquist LW, Racaniello VR, Skalka AM, (2009) Principles of Virology. SciELO Espana.
17. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, et al. (2002) C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76: 6841-6844.
18. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP, (2000) A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A 97: 13871-13876.
19. Timmins J, Schoehn G, Ricard-Blum S, Scianimanico S, Vernet T, et al. (2003) Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol 326: 493-502.
20. Gupta M, Mahanty S, Ahmed R, Rollin PE, (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284: 20-25.
21. Hensley LE, Young HA, Jahrling PB, Geisbert TW, (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80: 169-179.
22. Rubins KH, Hensley LE, Wahl-Jensen V, Daddario DiCaprio KM, Young HA, et al. (2007) The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 8: R174.
23. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, et al. (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179 Suppl 1: S188-191.
24. Yen JY, Garamszegi S, Geisbert JB, Rubins KH, Geisbert TW, et al. (2011) Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation. J Infect Dis 204 Suppl 3: S1043-1052.
25. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, et al. (2014) Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis doi: 10.1093/infdis/jiu088.
26. Sanchez A (2001) Ebola Viruses: Wiley Online Library.
27. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW, (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 17: 390-400.
28. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, et al. (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188: 1630-1638.
29. Bray M, Geisbert TW, (2005) Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37: 1560-1566.
30. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
31. Smyth GK (2005) Limma: linear models for microarray data; Gentleman R CV, Dudoit S, Irizarry R, and Huber W., editor. New York: Springer.
32. Team RDC (2010) R: A language and environment for statistical computing. In: Computing RFfS, editor. Vienna, Austria.
33. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, et al. (2007) A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700-2707.
34. Smyth GK, Speed T, (2003) Normalization of cDNA microarray data. Methods 31: 265-273.
35. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
36. de Hoon MJ, Imoto S, Nolan J, Miyano S, (2004) Open source clustering software. Bioinformatics 20: 1453-1454.
37. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
38. Saldanha AJ, (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.
39. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
40. Medigeshi GR, Hirsch AJ, Brien JD, Uhrlaub JL, Mason PW, et al. (2009) West nile virus capsid degradation of claudin proteins disrupts epithelial barrier function. J Virol 83: 6125-6134.
41. Kato N, Ji G, Wang Y, Baba M, Hoshida Y, et al. (2005) Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42: 846-853.
42. Lee JW, Liao PC, Young KC, Chang CL, Chen SS, et al. (2011) Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein. J Proteome Res 10: 4522-4534.
43. Shin HJ, Kim SS, Cho YH, Lee SG, Rho HM, (2002) Host cell proteins binding to the encapsidation signal epsilon in hepatitis B virus RNA. Arch Virol 147: 471-491.
44. Gomila RC, Martin GW, Gehrke L, (2011) NF90 binds the dengue virus RNA 3′ terminus and is a positive regulator of dengue virus replication. PLoS One 6: e16687.
45. Wang P, Song W, Mok BW, Zhao P, Qin K, et al. (2009) Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J Virol 83: 7850-7861.
46. Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, et al. (2009) Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J Gen Virol 90: 1600-1610.
47. Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, et al. (2011) Antiviral properties of lactoferrin-a natural immunity molecule. Molecules 16: 6992-7018.
48. Valenti P, Antonini G, (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62: 2576-2587.
49. Valimaa H, Tenovuo J, Waris M, Hukkanen V, (2009) Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virol J 6: 53.
50. Zheng Y, Zhang W, Ye Q, Zhou Y, Xiong W, et al. (2012) Inhibition of Epstein-Barr virus infection by lactoferrin. J Innate Immun 4: 387-398.
51. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM, (2013) Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 110: 1881-1886.
52. Sion-Vardy N, Lasarov I, Delgado B, Gopas J, Benharroch D, et al. (2009) Measles virus: evidence for association with lung cancer. Exp Lung Res 35: 701-712.
53. Kakugawa S, Shimojima M, Neumann G, Goto H, Kawaoka Y, (2009) RuvB-like protein 2 is a suppressor of influenza A virus polymerases. J Virol 83: 6429-6434.
54. Shabman RS, Leung DW, Johnson J, Glennon N, Gulcicek EE, et al. (2011) DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis 204 Suppl 3: S911-918.
55. Jopling CL, Schutz S, Sarnow P, (2008) Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4: 77-85.
56. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P, (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
57. Ambroise C, McLachlan GJ, (2002) Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 99: 6562-6566.
58. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
59. Simon R, Radmacher MD, Dobbin K, McShane LM, (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18.
60. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, et al. (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106: 2827-2836.
61. Smith EC, Thon JN, Devine MT, Lin S, Schulz VP, et al. (2012) MKL1 and MKL2 play redundant and crucial roles in megakaryocyte maturation and platelet formation. Blood 120: 2317-2329.
62. Volchkov VE, Volchkova VA, Chepurnov AA, Blinov VM, Dolnik O, et al. (1999) Characterization of the L gene and 5′ trailer region of Ebola virus. J Gen Virol 80 (Pt 2) (): 355-362.
63. Lazo PA, Santos CR, (2011) Interference with p53 functions in human viral infections, a target for novel antiviral strategies? Rev Med Virol 50doi: 10.1002/rmv.696.
64. Collot-Teixeira S, Bass J, Denis F, Ranger-Rogez S, (2004) Human tumor suppressor p53 and DNA viruses. Rev Med Virol 14: 301-319.
65. Turpin E, Luke K, Jones J, Tumpey T, Konan K, et al. (2005) Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication. J Virol 79: 8802-8811.
66. Marques JT, Rebouillat D, Ramana CV, Murakami J, Hill JE, et al. (2005) Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol 79: 11105-11114.
67. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, et al. (2008) Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 205: 1929-1938.
68. Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, et al. (2010) The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J Biol Chem 285: 6904-6912.
69. Thomas A, Giesler T, White E, (2000) p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene 19: 5259-5269.
70. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ, (2006) CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314: 294-297.
71. Zhang X, Tang N, Hadden TJ, Rishi AK, (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys 1813: 1978-1986.
72. Witko-Sarsat V, Mocek J, Bouayad D, Tamassia N, Ribeil JA, et al. (2010) Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival. J Exp Med 207: 2631-2645.
73. Henderson AJ, Calame KL, (1997) CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc Natl Acad Sci U S A 94: 8714-8719.
74. Henderson AJ, Connor RI, Calame KL, (1996) C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Immunity 5: 91-101.
75. Schwartz C, Catez P, Rohr O, Lecestre D, Aunis D, et al. (2000) Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. J Virol 74: 65-73.
76. Mohan M, Aye PP, Borda JT, Alvarez X, Lackner AA, (2008) CCAAT/enhancer binding protein beta is a major mediator of inflammation and viral replication in the gastrointestinal tract of simian immunodeficiency virus-infected rhesus macaques. Am J Pathol 173: 106-118.
77. Choi BH, Park GT, Rho HM, (1999) Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem 274: 2858-2865.
78. Mahe Y, Mukaida N, Kuno K, Akiyama M, Ikeda N, et al. (1991) Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 266: 13759-13763.
79. Wu FY, Wang SE, Chen H, Wang L, Hayward SD, et al. (2004) CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J Virol 78: 4847-4865.
80. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, et al. (1997) HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272: 14883-14892.
81. Hivin P, Gaudray G, Devaux C, Mesnard JM, (2004) Interaction between C/EBPbeta and Tax down-regulates human T-cell leukemia virus type I transcription. Virology 318: 556-565.
82. Grant C, Nonnemacher M, Jain P, Pandya D, Irish B, et al. (2006) CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology 348: 354-369.
83. Bauknecht T, Shi Y, (1998) Overexpression of C/EBPbeta represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein. J Virol 72: 2113-2124.